Literature DB >> 2892870

Proposed delusional depression subtypes: preliminary evidence from a retrospective study of phenomenology and treatment course.

T A Aronson1, S Shukla, A Hoff, B Cook.   

Abstract

An analysis of the phenomenology and treatment course of 52 subjects with delusional depression suggests that there may be various subtypes: bipolar, early-onset unipolar and possibly a late-onset unipolar. The bipolar subgroup tended to relapse in different but always psychotic directions, and was resistant to lithium carbonate treatment alone. Treatment refractoriness, delusional depressive recurrences, and a dementia-like presentation were associated with a small late-onset subgroup. A high rate of delusionally depressive relapses also characterized the early-onset unipolar group, however, patients with single episodes were found only in this subgroup.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2892870     DOI: 10.1016/0165-0327(88)90073-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

Review 1.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

2.  Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients.

Authors:  M Heslin; J M Lappin; K Donoghue; B Lomas; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; G A Doody; P Dazzan; T J Craig; C Morgan
Journal:  Schizophr Res       Date:  2016-05-26       Impact factor: 4.939

Review 3.  The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines.

Authors:  Konstantinos N Fountoulakis; Allan Young; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Pierre Blier; Hans Jurgen Moeller; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.